You make some good points:

1. You would think that an organization like Abbott would distance themselves rapidly from Biocurex if they found the technology to be weak. However, for all we know, they are conducting a double blind clinical trial that isn't complete.
2. The science writer you mention joins a lengthy club of people "in the know" who have never heard of this technology or this company. This relates to the point I was making in an earlier post: if the technology is as good as stated, management is doing a poor job of giving it credible exposure.

One thing that has kept my interest is Dr Gold's "involvement".

If this technology does what Dr Moro claims, it should be a slam dunk.